Avalon GloboCare (NASDAQ:ALBT) Stock Price Down 4.8% – Should You Sell?

Avalon GloboCare Corp. (NASDAQ:ALBT)’s share price dropped 4.8% during trading on Tuesday . The stock traded as low as $0.38 and last traded at $0.4130. Approximately 328,981 shares changed hands during trading, a decline of 95% from the average daily volume of 6,030,406 shares. The stock had previously closed at $0.4340.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Avalon GloboCare in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Avalon GloboCare has an average rating of “Sell”.

Avalon GloboCare Price Performance

The stock has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $1.26. The company has a market cap of $3.45 million, a P/E ratio of -0.12 and a beta of 0.10.

Avalon GloboCare (NASDAQ:ALBT) last posted its earnings results on Monday, March 30th. The company reported $0.46 earnings per share for the quarter.

Avalon GloboCare Company Profile

Avalon GloboCare is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection.

Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies.